



Cite this: *Med. Chem. Commun.*, 2017, 8, 2164

Correction: Development of highly active anti-*Pneumocystis* bisbenzamidines: insight into the influence of selected substituents on the *in vitro* activity

D. Maciejewska,^{*a} J. Żabiński,^a M. Rezler,^a P. Kaźmierczak,^a M. S. Collins,^{bc} L. Ficker^{bc} and M. T. Cushion^{*bc}

DOI: 10.1039/c7md90042b

rsc.li/medchemcomm

Correction for 'Development of highly active anti-*Pneumocystis* bisbenzamidines: insight into the influence of selected substituents on the *in vitro* activity' by D. Maciejewska *et al.*, *Med. Chem. Commun.*, 2017, 8, 2003–2011.

The authors regret that on page 7 of their article the name for compound 13 contains an error. The correct name for 13 is: 1,5-bis(4-amidino-2-nitrophenoxy)-3-oxapentane dihydrochloride (with -2- instead of -3-nitrophenoxy).

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

^a Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1 Street, 02-097 Warsaw, Poland. E-mail: dmaciejewska@wum.edu.pl

^b Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA.
E-mail: cushionmt@ucmail.uc.edu

^c Cincinnati Veterans Affairs Medical Center, 3200 Vine Street, Cincinnati, OH 45220, USA